Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

06 Mar, 2021

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification
Photo by Charles Forerunner on Unsplash

– Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
– It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
– Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
– The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.

Biopharma Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: